Latest News

Ivonescimab plus chemotherapy significantly improved overall survival compared with durvalumab plus chemotherapy in patients with previously untreated advanced biliary tract cancer.

Andrew Bzowyckyj, PharmD, explains how pharmacists can use albuminuria, ejection fraction, and inflammation to drive earlier CKM risk stratification and patient care.

A diabetologist who lives with type 1 diabetes weighs in on real-time ketone monitoring and what it means for at-risk patients.

Investigators say the nanoparticle candidate's speedy manufacturing process and slow-mutating target could reshape how the field responds to emerging flu strains.

Kidney-protective therapy is now layered. How pharmacists screen, stage by KDIGO, stagger ACE/ARB, SGLT2, GLP-1, and finerenone, and cut CV risk.

CK0803 is an investigational allogeneic cord blood–derived regulatory T-cell therapy designed to target neuroinflammation in amyotrophic lateral sclerosis.

Daraxonrasib, an oral RAS inhibitor, was approved for adults with metastatic pancreatic adenocarcinoma after prior systemic therapy or when multiagent systemic therapy is not appropriate.

New data show Opill reaches uninsured, rural, and younger patients—putting pharmacists at the center of daily dosing counseling.

The FDA has expanded the approval of dolutegravir expands access to a second-generation integrase inhibitor for infants in the neonatal period.

Abbott's Libre Duo 10 Day tracks both glucose and ketones to flag rising DKA risk in people with diabetes 2 years and older.

Sunburn and tanning signal DNA damage—learn SPF 30+ sunscreen tips, reapplication, and medication photosensitivity for skin cancer prevention.

The FDA has approved 2 zanidatamab-hrii–based regimens following phase 3 results demonstrating significant improvements in progression-free survival.

The first single-biomarker blood test is cleared for both rule-in and rule-out of amyloid pathology in primary and specialty care.

Nipocalimab is the first therapy approved specifically for wAIHA, a rare, life-threatening autoantibody disease driving red blood cell destruction.

Tracking 3-year changes in the heart stress marker separated older adults whose risk climbed from those whose risk resolved.

Certifying pharmacy technicians to administer immunizations streamlines workflow, combats vaccine misinformation, and positions pharmacies to fill a coming gap in physician access.

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, explains how pharmacists can spot metabolic dysfunction-associated steatotic liver disease (MASLD) risk, weigh GLP-1 and MASH therapies, and pair medication with lifestyle change.

A lesser-known viral protein may drive both the hyperinflammation and vascular damage seen in severe and long COVID-19.

The FDA has granted fast track designation to ERAS-0015, an investigational oral pan-RAS molecular glue that has shown early antitumor activity in previously treated KRAS G12X pancreatic ductal adenocarcinoma.

The FDA-granted priority review raises the possibility of an immunotherapy-first approach that could allow some patients to avoid chemotherapy, radiation, and surgery.

Novo Nordisk's false-advertising case against Eli Lilly turns on GLP-1 dosing—here's the context pharmacists need when patients ask which drug is better.